RetinaLogik, a Calgary-based health tech company, has successfully closed a $1.1 million funding round and secured Health Canada’s Class II medical device approval for its AI-powered virtual reality (VR) eye exam platform.
The company’s VR-AI technology enables eye care professionals to conduct essential tests, such as visual field exams, with greater efficiency and accessibility. Its portable headset, which is also ISO-13485 and MDSAP certified and FDA registered, aims to streamline the testing process, significantly reducing exam times and equipment costs—by as much as 90% compared to traditional systems. The device also includes multilingual support to enhance communication in clinics.
“Achieving these milestones marks a proud moment for our organization,” said RetinaLogik CEO Dr. Sarhan. “We’ve developed a solution that not only makes eye care more efficient but also more affordable and accessible. With the support of our investors and partners, we’re excited to continue growing and improving the future of eye care for everyone.”
The funding round was co-led by Spring Impact Capital and UCeed Funds, both of which have backed RetinaLogik’s growth.
“Over the past two years, the RetinaLogik team has built a groundbreaking VR platform that delivers unparalleled clinical reliability,” said Nikhi, Operating Partner at UCeed Funds. Graham Day, Managing Partner at Spring Impact Capital, emphasized the company’s market potential: “By enhancing access to quality eye care diagnostics and improving clinic efficiency, they are set to make a meaningful impact on communities while achieving commercial success.”
RetinaLogik’s progress has also been supported by Alberta Innovates, with Vice President of Health Trevor Lynn noting the company’s success in commercializing health innovation through the Accelerating Innovations into Care (AICE) program.
With Health Canada approval secured, RetinaLogik now plans to scale its platform across North America and beyond, aiming to close critical gaps in vision care by enabling earlier detection and treatment of vision-threatening conditions.
Leave a Reply